Acadian Asset Management LLC Makes New Investment in Bruker Corporation $BRKR

Acadian Asset Management LLC purchased a new position in Bruker Corporation (NASDAQ:BRKR) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 50,156 shares of the medical research company’s stock, valued at approximately $2,093,000.

Other hedge funds have also bought and sold shares of the company. Pinnacle Bancorp Inc. purchased a new stake in Bruker in the 1st quarter worth $29,000. Allworth Financial LP lifted its stake in Bruker by 92.4% in the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock worth $30,000 after purchasing an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Bruker by 1,354.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock worth $33,000 after purchasing an additional 745 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in Bruker in the 1st quarter worth $42,000. Finally, MassMutual Private Wealth & Trust FSB raised its position in shares of Bruker by 274.9% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company’s stock valued at $46,000 after buying an additional 800 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Wells Fargo & Company decreased their target price on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 5th. Jefferies Financial Group set a $60.00 target price on shares of Bruker and gave the company a “buy” rating in a research report on Monday, August 4th. Citigroup decreased their target price on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a research report on Monday, August 4th. Bank of America decreased their target price on shares of Bruker from $61.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, June 26th. Finally, Stifel Nicolaus set a $40.00 target price on shares of Bruker and gave the company a “hold” rating in a research report on Tuesday, August 5th. Five investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $51.30.

Insider Activity

In other news, Director Cynthia M. Friend sold 3,535 shares of the stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $32.25, for a total transaction of $114,003.75. Following the transaction, the director directly owned 18,016 shares in the company, valued at approximately $581,016. This trade represents a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 27.30% of the company’s stock.

Bruker Price Performance

Shares of BRKR stock opened at $33.26 on Wednesday. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $72.94. The stock has a market capitalization of $5.05 billion, a price-to-earnings ratio of 63.96, a P/E/G ratio of 4.45 and a beta of 1.21. The stock has a fifty day simple moving average of $35.65 and a two-hundred day simple moving average of $38.69. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31.

Bruker (NASDAQ:BRKR) last issued its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a return on equity of 17.89% and a net margin of 2.31%.The firm had revenue of $797.40 million during the quarter, compared to analysts’ expectations of $811.17 million. During the same quarter in the prior year, the company posted $0.52 earnings per share. Bruker’s quarterly revenue was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be paid a dividend of $0.05 per share. The ex-dividend date is Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. Bruker’s dividend payout ratio (DPR) is currently 38.46%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.